Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 4

Tobacco smoking cessation management: integrating varenicline in current practice

Authors Laurence M Galanti

Published Date September 2008 Volume 2008:4(4) Pages 837—845

DOI http://dx.doi.org/10.2147/VHRM.S3250

Published 5 September 2008

Laurence M Galanti

Clinique Universitaire UCL, Mont-Godinne, Yvoir, Belgium

Abstract: Tobacco smoking is widespread and is one of the world’s most prevalent modifiable risk factors for morbidity and mortality. It is important to facilitate smoking cessation better in order to reduce the health consequences of tobacco use. The most effective approach assisting smokers in their quit attempts combines both pharmacotherapy and nonpharmacological interventions. This review summarizes the latest international epidemiological data available on tobacco use, considers the associated effects on health, and reviews existing policies against tobacco use. Among the interventions for smoking cessation, the three major pharmacotherapies (which have demonstrated efficacy when combined with behavioral support) are discussed: nicotine replacement therapy (NRT), bupropion, and varenicline. As the newest pharmacotherapy made available in this area, particular consideration is given to varenicline, and a review of our clinical experience is offered.

Keywords: tobacco smoking cessation, nicotinic substitution, nicotine replacement therapy (NRT), bupropion, varenicline

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Occult nonmetallic intraocular foreign bodies presenting as fulminant uveitis: a case series and review of the literature

Sychev YV, Verner-Cole EA, Suhler EB, Stout JT, Vemulakonda GA

Clinical Ophthalmology 2013, 7:1747-1751

Published Date: 2 September 2013

Cytoprotective and enhanced anti-inflammatory activities of liposomal piroxicam formulation in lipopolysaccharide-stimulated RAW 264.7 macrophages

Chiong HS, Yong YK, Ahmad Z, Sulaiman MR, Zakaria ZA, Yuen KH, Hakim MN

International Journal of Nanomedicine 2013, 8:1245-1255

Published Date: 22 March 2013

Colloidal gold-loaded, biodegradable, polymer-based stavudine nanoparticle uptake by macrophages: an in vitro study

Basu S, Mukherjee B, Chowdhury SR, Paul P, Choudhury R, Kumar A, Mondal L, Hossain CM, Maji R

International Journal of Nanomedicine 2012, 7:6049-6061

Published Date: 13 December 2012

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

Dejager S, Schweizer A, Foley JE

Vascular Health and Risk Management 2012, 8:339-348

Published Date: 18 May 2012

Microemulsion-based novel transdermal delivery system of tetramethylpyrazine: preparation and evaluation in vitro and in vivo

Zhao JH, Ji L, Wang H, Chen ZQ, Zhang YT, Liu Y, Feng NP

International Journal of Nanomedicine 2011, 6:1611-1619

Published Date: 9 August 2011

Difluprednate ophthalmic emulsion 0.05% (Durezol®) administered two times daily for managing ocular inflammation and pain following cataract surgery

Stephen Smith, Douglas Lorenz, James Peace, et al.

Clinical Ophthalmology 2010, 4:983-991

Published Date: 30 August 2010

Analysis of sFas IL-6 levels in thyroid-associated ophthalmopathy: Pre- or poststeroid pulse treatment

Kimihito Maeda, Yuichiro Ohara, Masato Hashimoto, Hiroshi Ohguro

Clinical Ophthalmology 2008, 2:609-612

Published Date: 5 October 2008